Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

COVID-19 booster programme

- PMLiVE

AZ needs more data on olaparib, says FDA panel

Agency advisers demands more safety information on ovarian cancer drug

AZ expands its mHealth services with new COPD initiative

Partners with Exco InTouch to launch Me&MyCOPD programme

- PMLiVE

ADA: AZ plans to file Onglyza/Forxiga pill by year-end

Diabetes prospects could help justify decision to turn down Pfizer bid

- PMLiVE

AstraZeneca has clearer route to Movantik approval in US

Won't have to carry out cardiovascular outcomes study prior to approval

- PMLiVE

AZ licenses asthma infection drug from Synairgen

Boosts respiratory portfolio with $232m deal

- PMLiVE

AstraZeneca backs mental health campaign

Pharma company supports Mental Health America

- PMLiVE

ASCO: AstraZeneca shows off cancer immunotherapy

MEDI4736 could rival Merck & Co’s anti-PD1 inhibitor pembrolizumab

- PMLiVE

FDA fast-tracks new AstraZeneca antibiotic

Speeds up review period for AZD0914 in gonorrhoea

- PMLiVE

ASCO: AZ’s ovarian cancer combination aces trial

Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months

- PMLiVE

Interview: AstraZeneca’s Susan Galbraith

As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer

- PMLiVE

Pfizer abandons AZ takeover bid – for now

Deadline for deal passes after four rejected offers

- PMLiVE

No mass revolt from AZ shareholders on Pfizer takeover

Company’s decision to stand firm is applauded by investors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links